Press Releases

04.27.2017

Insphero Announces Agreement With Pfizer To Develop Novel Assays For Predicting Drug-Induced Liver Injury

04.27.2017

Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

04.25.2017

Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

04.25.2017

Circle Pharma Announces Expansion Of Series A Financing And Appointment Of James C. Lu To Its Board

04.25.2017

Domain Therapeutics And Pfizer Inc. Enter Into Collaboration Agreement On Biosensall™

04.24.2017

Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals

04.21.2017

Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

04.21.2017

Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries

04.20.2017

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

04.20.2017

PSI And Pfizer Partner To Address Hypertension In Vietnam And Myanmar

03.31.2017

IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

03.27.2017

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)